Annals of Oncology Advance Access originally published online on February 22, 2005
Annals of Oncology 2005 16(5):780-785; doi:10.1093/annonc/mdi157
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
1 Division of Hematology–Oncology, University of Pittsburgh School of Medicine; 2 Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
* Correspondence to: Professor C. P. Belani, University of Pittsburgh School of Medicine, 5150 Centre Avenue, UPMC Cancer Pavilion, Ste #552, Pittsburgh, PA 15232, USA. Tel: +1 412 648 6619; Fax: +1 412 664 6579. Email: belanicp{at}upmc.edu
Background:: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome.
Patients and methods:: Patients (n=199) with advanced NSCLC were treated with gefitinib (250 mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%.
Results:: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1–7.1] and median time to progression was 3 months (95% CI 2.0–3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P <0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival.
Conclusions:: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.
Key words: gefitinib, non-small cell lung cancer, performance status, skin rash
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Lee, T. Buchler, T. Joseph, and C. Lai Bilateral Eardrum Perforation After Long-Term Treatment With Erlotinib J. Clin. Oncol., May 20, 2008; 26(15): 2582 - 2584. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, M. Salvatici, G. Veronesi, F. Veglia, C. Fiorentini, et al. Increased Perioperative N-Terminal Pro-B-Type Natriuretic Peptide Levels Predict Atrial Fibrillation After Thoracic Surgery for Lung Cancer Circulation, March 20, 2007; 115(11): 1339 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cusatis, V. Gregorc, J. Li, A. Spreafico, R. G. Ingersoll, J. Verweij, V. Ludovini, E. Villa, M. Hidalgo, A. Sparreboom, et al. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib J Natl Cancer Inst, December 6, 2006; 98(23): 1739 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tan, D. F. Moore, M. Hidalgo, J. H. Doroshow, E. A. Poplin, S. Goodin, D. Mauro, and E. H. Rubin Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors Clin. Cancer Res., November 1, 2006; 12(21): 6517 - 6522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib Cancer Res., August 15, 2006; 66(16): 8163 - 8171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, S. Harita, K. Gemba, T. Yonei, A. Bessho, and M. Tanimoto Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience Ann. Onc., November 1, 2005; 16(11): 1817 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Segaert and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann. Onc., September 1, 2005; 16(9): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R)) Oncologist, September 1, 2005; 10(8): 579 - 589. [Abstract] [Full Text] [PDF]
|
|